Bausch + Lomb Corp.(us:BLCO)
14.49
+2.55%
Updated on 2025-03-31
Open:13.94
Close:14.49
High:14.69
Low:13.94
Prev Close:14.13
Volume:1.90M
Turnover:26.84M
Turnover Ratio:0.54%
Shares:352.47M
MarketCap:5.11B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 107 | 40725425 | 11.57% | 22 | 34 | 36 |
| 2024-03-31 | 109 | 37569337 | 10.69% | 20 | 28 | 46 |
| 2023-12-31 | 105 | 38842328 | 11.07% | 21 | 35 | 32 |
| 2023-09-30 | 91 | 42447778 | 12.10% | 16 | 23 | 29 |
| 2023-06-30 | 88 | 43542681 | 12.42% | 14 | 21 | 37 |
| 2023-03-31 | 93 | 43322552 | 12.37% | 10 | 30 | 37 |
| 2022-12-31 | 103 | 44659716 | 12.76% | 31 | 24 | 32 |
| 2022-09-30 | 105 | 43526928 | 12.44% | 34 | 13 | 53 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Fil Ltd | 8185200 | 2.33% | 70205 | 0.86% |
| 2024-03-31 | Goldentree Asset Management Lp | 4715829 | 1.34% | 0 | |
| 2024-03-31 | Maple Rock Capital Partners Inc. | 3745062 | 1.07% | 0 | |
| 2024-03-31 | Icahn Carl C | 3500000 | 1.00% | 0 | |
| 2024-03-31 | River Road Asset Management, Llc | 1888065 | 0.54% | -50142 | -2.59% |
| 2024-03-31 | Alberta Investment Management Corp | 1591793 | 0.45% | 240000 | 17.75% |
| 2024-03-31 | Citadel Advisors Llc | 1585846 | 0.45% | -960456 | -37.72% |
| 2024-03-31 | Nomura Holdings Inc | 1256181 | 0.36% | 0 | |
| 2024-03-31 | Whitebox Advisors Llc | 1206303 | 0.34% | 273484 | 29.32% |
| 2024-03-31 | Freshford Capital Management, Llc | 1165280 | 0.33% | -588843 | -33.57% |
About
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Address:520 Applewood Crescent
Website:http://www.bausch.com
Market Movers